ArticleNeuro-oncology2022
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 69 citations in OpenAlex.
- Contribution of cognitive function and fatigue to health-related quality of life in patients withNeuro-oncology practice · 2026Article
- An Expanded T2-FLAIR Mismatch Phenotype in IDH-Mutant Astrocytomas.Journal of magnetic resonance imaging : JMRI · 2026Article
- Real-World Validation of the Clinical Distinctiveness of IDH-Mutant Glioblastoma in the SEER Transition Era: A Population-Based Study Integrating Machine Learning.Brain and behavior · 2026Article
- Development of a metabolic subtype classifier for low-grade glioma to guide precision therapy.Discover oncology · 2026Article
- SEER-Medicaid and SEER-Medicare data for neuro-oncology research.Journal of neuro-oncology · 2026Review
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022.Neuro-oncology · 2025Article
- CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.Neuro-oncology · 2025Article
- Enhanced MRI brain tumor detection using deep learning in conjunction with explainable AI SHAP based diverse and multi feature analysis.Scientific reports · 2025Article
- Regulation of the brain tumor microenvironment by focused ultrasound.Molecular therapy. Oncology · 2025Review
- Dysregulation of Iron Homeostasis Mediated by FTH Increases Ferroptosis Sensitivity in TP53-Mutant Glioblastoma.Neuroscience bulletin · 2025Article
- Provider Volume Impacts Neurosurgical Procedure Selection in Older Patients With High-Grade Glioma.Cancer medicine · 2025Article
- Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients.Clinical chemistry · 2025Article
- Integrating quantitative DCE-MRI parameters and radiomic features for improved IDH mutation prediction in gliomas.Frontiers in oncology · 2025Article
- A Novel Signature of Disulfidptosis-Related lncRNAs Predicts Prognosis in Glioma: Evidence From Bioinformatic Analysis and Experiments.International journal of genomics · 2025Article
- Development and validation of a nomogram for predicting cancer-related fatigue in patients with glioma: a multicenter study.Frontiers in oncology · 2025Article
- MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma.Neuro-oncology · 2024Article
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.Neuro-oncology · 2024Article
- Review
- A Unified Pipeline for Simultaneous Brain Tumor Classification and Segmentation Using Fine-Tuned CNN and Residual UNet Architecture.Life (Basel, Switzerland) · 2024Article
- Glioma.Nature reviews. Disease primers · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundSelected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables and described the epidemiology of molecularly defined brain tumor types.
methodsBrain tumor patients with histopathologically confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the characteristics and age-adjusted incidence rates per 100 000 population of molecularly defined brain tumors with 95% confidence intervals (95% CI).
resultsBMM completeness across the applicable tumor types was 75%-92% and demonstrated favorable coding validity. IDH-wildtype glioblastomas' incidence rate was 1.74 (95% CI: 1.69-1.78), as compared to 0.14 for WHO grade 2 (95% CI: 0.12-0.15), 0.15 for grade 3 (95% CI: 0.14-0.16), and 0.07 for grade 4 (95% CI: 0.06-0.08) IDH-mutant astrocytomas. Irrespective of WHO grade, IDH mutation prevalence was highest in adolescent and young adult patients, and IDH-mutant astrocytomas were more frequently MGMT promoter methylated. Among pediatric-type tumors, the incidence rate was 0.06 for H3K27M-mutant diffuse midline gliomas (95% CI: 0.05-0.07), 0.03 for SHH-activated/TP53-wildtype medulloblastomas (95% CI: 0.02-0.03), and <0.01 for both C19MC-altered embryonal tumor with multilayered rosettes and RELA-fusion ependymomas.
conclusionsOur findings illustrate the success of developing a dedicated, integrated diagnosis variable, which provides critical molecular information about brain tumors related to accurate diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.